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Background: The novel small molecule R118 and the biguanide metformin, a first-line therapy for type 2 diabetes
(T2D), both activate the critical cellular energy sensor 5′-AMP-activated protein kinase (AMPK) via modulation of
mitochondrial complex I activity. Activation of AMPK results in both acute responses and chronic adaptations, which
serve to restore energy homeostasis. Metformin is thought to elicit its beneficial effects on maintenance of glucose
homeostasis primarily though impacting glucose and fat metabolism in the liver. Given the commonalities in their
mechanisms of action and that R118 also improves glucose homeostasis in a murine model of T2D, the effects of
both R118 and metformin on metabolic pathways in vivo were compared in order to determine whether R118
elicits its beneficial effects through similar mechanisms.
Results: Global metabolite profiling of tissues and plasma from mice with diet-induced obesity chronically treated
with either R118 or metformin revealed tissue-selective effects of each compound. Whereas metformin treatment
resulted in stronger reductions in glucose and lipid metabolites in the liver compared to R118, upregulation of
skeletal muscle glycolysis and lipolysis was apparent only in skeletal muscle from R118-treated animals. Both
compounds increased β-hydroxybutyrate levels, but this effect was lost after compound washout. Metformin,
but not R118, increased plasma levels of metabolites involved in purine metabolism.
Conclusions: R118 treatment but not metformin resulted in increased glycolysis and lipolysis in skeletal muscle.
In contrast, metformin had a greater impact than R118 on glucose and fat metabolism in liver tissue.
Keywords: AMPK, Metformin, Complex I, Mitochondria, Diabetes, Metabolomics, Skeletal muscle, Metabolism,
Small molecule, Diet-induced obese miceBackground
The widely used type 2 diabetes therapy metformin
and the recently reported investigational drug R118
(international application publication no. WO 2012/
016217, February 2, 2012) are both mitochondrial
complex I inhibitors [1-3] that mediate their beneficial
effects on glucose homeostasis partly through modulation
of the 5′-adenosine monosphate-activated protein kinase
(AMPK), a critical sensor of cellular energy status. R118 is* Correspondence: yjenkins@rigel.com
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unless otherwise stated.a mechanistic analog of the well-characterized small
molecule R419 [4] and activates AMPK by inhibiting
mitochondrial complex I with a potency of ~70 nM,
comparable to the reported R419 potency of 100 nM.
Chronic R118 treatment was recently shown to improve
exercise performance in aged, obese mice that display
many of the functional and molecular characteristics of
peripheral arterial disease [1]. Metformin also activates
AMPK via complex I inhibition, although the potency
displayed against complex I, and consequent AMPK
activation, is substantially weaker (mM) compared to
R118. However, glucose homeostasis is maintained byLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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mechanisms, with the liver thought to be the primary site
of metformin action [5-10]. The mechanistic bases of
metformin’s therapeutic benefits are still being debated
despite extensive characterization of its effects both in vitro
and in vivo. Suppression of hepatic glucose production
by metformin has been attributed to a block in glucagon-
stimulated glucose synthesis, which is mediated by a
decrease in adenylate cyclase activity resulting from the
inhibition of complex I [11]. Metformin was also recently
shown to inhibit mitochondrial glycerophosphate dehydro-
genase (mGPD), which suppresses glucose production from
lactate and glycerol precursors [12]. In addition, chronic
metformin treatment also decreased liver lipid accumula-
tion by AMPK-mediated inhibition of acetyl-CoA carboxyl-
ase activity (ACC), which also contributes to increased
insulin sensitivity [13].
Here, we extend and complement the existing studies
by analyzing the chronic effects on metabolic pathways
in mice with diet-induced obesity (DIO) treated with
R118 or metformin. We performed global metabolite
profiling on tissues and plasma from R118-treated DIO
mice to better understand the effects of chronic adminis-
tration of the class of compounds represented by R118 on
nutrient metabolism in vivo. Further, the activity of R118
was directly compared to that of metformin. Given the
similarities in their molecular mechanisms of action, we
sought to identify both the common and the distinguishing
features between R118 and metformin on biochemical
pathways in liver, skeletal muscle, and adipose tissue.
Methods
Animal care and treatment
Male C57BL/6 J DIO mice fed with a high-fat diet (HFD,
60% of kcal from fat) since 6 weeks of age were purchased
from Jackson Laboratories (Bar Harbor, ME). DIO mice
were acclimated at Rigel for 4 weeks prior to study
initiation. Mice were housed 4 per cage in a room
with a 12-12 hour light/dark cycle and were given
HFD (D12492, Research Diets, Inc., New Brunswick, NJ)
and drinking water ad libitum. Rigel’s Institutional Animal
Care and Use Committee approved all procedures (IACUC
Protocol No. Rigel 2-2012).
Metabolomics study
DIO mice (21 weeks of age, 17 weeks on HFD) were
weighed and randomized into study groups so that each
group had similar average body weight. Mice were
treated with either HFD (n = 12), HFD formulated with
200 mg/kg R118 (n = 12), or HFD formulated with 5 g/kg
metformin (n = 12). Dose selection for R118 was deter-
mined by identifying the compound level required to yield
an average 24 hour exposure similar to that required
for improvement of oral glucose tolerance by R118 indb/db leptin-receptor deficient mice (average Area Under
the Curve (AUC)0-24 of approximately 2300 ng•hr/mL, data
not shown). Dose titration for metformin was performed to
determine the minimum dose required for improvement in
oral glucose tolerance without accompanying body weight
reduction (data not shown). At 4 weeks of compound
treatment, an oral glucose tolerance test (OGTT) was
performed. Glucose was administered orally at 2 g/kg
following a 6-hour fast with food removal at 5 AM.
Tail vein bleeds were used to measure blood glucose at 0,
30, 60, 90, and 120 minutes after glucose challenge
(Breeze2, Bayer). At 5 weeks of treatment, 6 mice/treatment
group were euthanized by CO2 asphyxiation followed
by cardiac puncture at 6 AM. Liver, gastrocnemius
muscle, visceral adipose tissue, and plasma were collected
from each animal. Solid tissues were submerged in liquid
nitrogen immediately after collection. For the remaining 6
mice in each treatment group, compound-formulated
HFD was replaced with control HFD at 6 AM, followed
by liver, gastrocnemius muscle, white adipose tissue, and
plasma collection as above 24 hours after the chow
replacement. All samples were stored at -80°C prior
to shipment to Metabolon for unbiased metabolite analysis
(Durham, NC) [14-16]. Biochemical data were analyzed
using Welch’s two-sample t-tests.
Results
R118 has a stronger chronic effect on skeletal muscle
metabolism compared to liver and adipose tissue
DIO mice were treated using high fat diet formulated with
either R118 (200 mg/kg HFD) or metformin (5 g/kg HFD).
An OGTT test was performed after 4 weeks of treatment
to confirm the biologic activity of both compounds
(Additional file 1: Figure S1) prior to sample collection.
Oral glucose tolerance was improved without significant
effects on body weight at the doses utilized for both
compounds, increasing the likelihood that any observed
changes in biochemical pathways will be a direct result of
compound treatment, rather than indirectly due to body
weight alterations.
After functional confirmation of compound activity,
samples from the treated animals were collected under
two different conditions for metabolite profiling. Tissues
from half the animals in each treatment group were
harvested at 6 AM, towards the end of the 12 hour
active cycle when plasma compound concentrations
are at maximal levels. In order to determine the chronic
effects on metabolic pathways in vivo for both R118 and
metformin, compound-formulated HFD was replaced with
control HFD at 6 AM for the remaining animals in each
treatment group to wash out the drugs, with sample
collection 24 hours after chow replacement. Drug levels
were measured in the plasma samples from the two har-
vest conditions to confirm that compound concentrations
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Figure S2). Metformin plasma concentrations in mice
harvested at maximal compound levels were about
6.1 μg/mL, about 4-fold higher than plasma concentra-
tions reported after single administration of an 850 mg
metformin dose to T2D patients [17]. In the drug washout
samples, plasma metformin concentrations dropped to
about 0.05 μg/mL whereas R118 plasma concentrations
were below the limit of quantitation.
Comparison across skeletal muscle, liver and adipose
tissue of the total number of metabolites that were
significantly altered (P < 0.05) between each treatment
versus the HFD control shows differential responses to
R118 and metformin for each tissue profiled (Figure 1). In
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Figure 1 Biochemical changes detected in skeletal muscle, liver, and
metformin. Male HFD DIO C57BL/6 mice (21 weeks old, 17 weeks on HFD
or HFD formulated with 5 g/kg metformin (n = 12/group). After five weeks
collected for half of the mice in each group. For the remaining mice, comp
(washout), followed by similar sample collection. For each tissue, the numb
control HFD has p < 0.05 is shown in the graphs. Further breakdown of the si
compared to the control HFD is indicated by the color coding, where green i
increased with drug treatment relative to control HFD.HFD control for R118-treated animals compared to
metformin. In contrast, metformin treatment resulted
in more liver and adipose changes than R118. Under
conditions of drug washout, a similar number of biochem-
ical differences are maintained in skeletal muscle from
R118-treated mice, demonstrating that chronic R118
dosing leads to changes in skeletal muscle metabolism
that are sustained in the absence of drug. Metformin
effects on hepatic metabolism actually become more
pronounced in the washout samples, suggesting that
the immediate effects of compound treatment may
obscure the detection of chronic changes in biochem-
ical pathways. Although 18.5% of the total metabolites
detected in adipose tissue were significantly affected
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effects on adipose tissue are not sustained.
R118 affects both glucose and fat metabolism in skeletal
muscle
Figure 2 compares the effect of both R118 and metformin
treatment on glycolytic intermediates in skeletal muscle
measured after compound washout. R118-treated muscles
displayed significant elevations in intermediates produced
during the terminal steps of glycolysis, along with trending
increases in intermediates found in the initial enzymatic
steps. In addition, pyruvate levels were elevated without





































Figure 2 Increased skeletal muscle glycolysis in DIO mice chronically
17 weeks on HFD) were fed using control HFD, HFD formulated with 200 m
After five weeks of treatment, liver, skeletal muscle, adipose tissue, and plasma
mice, compound-formulated HFD was replaced with control HFD for 24 hour
skeletal muscle glycolytic intermediates for the drug washout samples are sho
indicate relative fold change for drug treatment compared to control HFD. Bian R118-mediated increase in glucose uptake and eventual
disposal via glycolysis and tricarboxylic acid cycle (TCA)
oxidation. In contrast to R118, metformin treatment
resulted in non-significant elevations in early glycolytic
intermediates with no discernible changes over control
HFD treatment downstream of fructose-6-phosphate,
suggesting that disposal of glucose in metformin-treated
skeletal muscle occurs via non-oxidative pathways.
Measurements of long chain fatty acids (LCFA) in
skeletal muscle from R118-treated animals reveals trending
elevations in some LCFA species concomitant with a
trending elevation in glycerol (Figure 3). This pattern



































treated with R118. Male HFD DIO C57BL/6 mice (21 weeks old,
g/kg R118, or HFD formulated with 5 g/kg metformin (n = 12/group).
were collected for half of the mice in each group. For the remaining
s (washout), followed by similar sample collection. Detected changes in
wn mapped onto the glycolysis pathway. Numbers in parentheses













R118 MET R118 MET
CTRL CTRL CTRL CTRL
myristate (14:0) 1.03 1.01 1.26 1.17
myristoleate (14:1n5) 1.19 1.12 1.17 1.08
pentadecanoate (15:0) 1.02 1.11 1.09 0.98
palmitate (16:0) 1.16 1.1 1.27 1.15
palmitoleate (16:1n7) 1.08 1.12 1.29 1.17
margarate (17:0) 1.08 1.08 1.29 1.15
10-heptadecenoate (17:1n7) 1.13 1.18 1.23 1.13
stearate (18:0) 1 1.02 1.18 1.1
oleate (18:1n9) 1.46 1.17 1.14 1.17
cis-vaccenate (18:1n7) 1.28 1.09 1.02 1.08
nonadecanoate (19:0) 0.99 1.06 1.1 1.05
10-nonadecenoate (19:1n9) 1.25 1.15 1.37 1.11
eicosenoate (20:1n9 or 11) 1.18 1.13 1.31 1.2
dihomo-linoleate (20:2n6) 1.2 1.15 1.5 1.26
mead acid (20:3n9) 1.17 1.08 1.63 1.05
arachidonate (20:4n6) 1.17 1.13 1.35 1.21
erucate (22:1n9) 1.09 1.09 1.37 1.13
docosadienoate (22:2n6) 1.44 1.15 1.41 1.22
adrenate (22:4n6) 1.26 0.91 1.05 1.01
Glycerolipid metabolism glycerol 1.12 1.05 1.06 1.03
Sub Pathway Biochemical Name
MAX CMP WASHOUT
Long Chain Fatty Acid
Figure 3 Increased skeletal muscle lipolysis in DIO mice chronically treated with R118. Male HFD DIO C57BL/6 mice (21 weeks old,
17 weeks on HFD) were fed using control HFD, HFD formulated with 200 mg/kg R118, or HFD formulated with 5 g/kg metformin (n = 12/group).
After five weeks of treatment, liver, skeletal muscle, adipose tissue, and plasma were collected for half of the mice in each group (max cmp). For
the remaining mice, compound-formulated HFD was replaced with control HFD for 24 hours (washout), followed by similar sample collection.
Heatmap of detected changes in skeletal muscle long chain fatty acids and glycerol for both R118 and metformin-treated mice shown relative to
control HFD is presented alongside a simple scheme illustrating the triacylglycerol lipolysis pathway. TAG = triacylglycerol, DAG = diacylglycerol,
MAG =monoacylglycerol, FA = fatty acid, ATGL = adipose triglyceride lipase, HSL = hormone sensitive lipase. Biochemical data were analyzed using
Welch’s two-sample t-tests.
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muscle from metformin-treated animals either in the
presence or absence of drug. Increases in free fatty
acids coincident with elevated glycerol are characteristic
features of triacylglycerol lipolysis, which suggests that
breakdown of intramuscular lipids is increased with
chronic R118 treatment.
R118 has limited effects on hepatic fatty acid and glucose
metabolism
Figure 4 shows the changes relative to the HFD control
in intermediates of glucose metabolism and long chain
fatty acids for R118 and metformin treatment. Metformin
treatment surprisingly did not dramatically impact hepatic
glucose metabolism with the caveat that the samples were
collected in the fed state where insulin suppression of glu-
cose production would be maximal. Some intermediates
were significantly elevated (glucose-6-phosphate, fructose-6-
phosphate) although lactate was decreased (non-significant).
Hepatic glucose did increase significantly when metformin
was withdrawn, which would support a drug-related effect
on hepatic glucose production.
Chronic metformin treatment resulted in more striking
changes in levels of hepatic LCFAs, with some increasing
while others decreased, possibly reflecting contributions
from both mitochondrial and peroxisomal lipid metabolism[18] as well as decreased LCFA synthesis. Although R118
possesses substantially greater potency in complex I inhib-
ition and AMPK activation in vitro compared to metformin
(69 nM versus 27 mM on complex I inhibition), its chronic
effects on hepatic glucose metabolism and LCFA levels
were much less apparent than metformin.
Increased 3-hydroxybutyrate (BHBA) is an acute response
to both R118 and metformin treatment
BHBA, a ketone body that is generated from acetyl CoA
derived usually from mitochondrial fat oxidation, was
significantly increased with chronic treatment of DIO
mice (Figure 5) across all sampled compartments with
R118 and most compartments with metformin (trending in
adipose tissue). In all matrices, BHBA levels were elevated
only in the presence of the drugs, remaining at control
HFD levels after drug washout despite changes in fatty acid
metabolism becoming more evident in the washout
samples for both R118 and metformin (Figures 3 and 4),
suggesting that elevated BHBA is an acute response to
each drug rather than a chronic adaptation.
R118 and metformin display differential effects on purine
metabolites
In plasma, several intermediates of purine breakdown
were significantly elevated in metformin-treated but not
Glucose 
Metabolism 
Long Chain Fatty 
Acids 
R118 MET R118 MET
CTRL CTRL CTRL CTRL
myristate (14:0) 1.01 0.76 0.93 0.79
myristoleate (14:1n5) 1 0.67 0.88 0.68
pentadecanoate (15:0) 1.13 0.82 1 1.18
palmitate (16:0) 0.97 0.94 1.02 1.03
palmitoleate (16:1n7) 0.94 0.68 0.86 0.76
margarate (17:0) 1.1 1.11 1.2 1.23
10-heptadecenoate (17:1n7) 1.04 0.76 0.96 0.85
stearate (18:0) 0.96 1.04 1.07 1.03
oleate (18:1n9) 0.99 0.72 0.93 0.78
cis-vaccenate (18:1n7) 0.95 0.72 0.77 0.61
stearidonate (18:4n3) 1.39 1.31 1.28 1.55
nonadecanoate (19:0) 0.94 0.94 1.17 1.11
10-nonadecenoate (19:1n9) 0.96 0.69 1.06 0.69
arachidate (20:0) 1.17 1.34 1.64 1.88
eicosenoate (20:1n9 or 11) 0.91 0.7 1.09 0.8
dihomo-linoleate (20:2n6) 1.05 0.8 1.11 0.82
arachidonate (20:4n6) 1.14 1.13 1.07 1.06
erucate (22:1n9) 1.16 0.97 1.59 1.39
docosadienoate (22:2n6) 1.04 0.96 1.45 1.2







R118 MET R118 MET
CTRL CTRL CTRL CTRL
glucose-6-phosphate 1.04 1.67 0.91 0.78
glucose 1.08 1.09 1.09 1.16
fructose-6-phosphate 1.15 1.66 1.07 0.98
3-phosphoglycerate 1 1.26 1.15 1.37
dihydroxyacetone 
phosphate 1.1 1.14 1.18 1.14
phosphoenolpyruvate 1.12 1.26 0.74 0.99
lactate 0.92 0.86 1.01 1.08
MAX CMP WASHOUT
Figure 4 Metformin has a more pronounced effect on hepatic glucose metabolism and long chain fatty acids compared to R118. Male
HFD DIO C57BL/6 mice (21 weeks old, 17 weeks on HFD) were fed using control HFD, HFD formulated with 200 mg/kg R118, or HFD formulated
with 5 g/kg metformin (n = 12/group). After five weeks of treatment, liver, skeletal muscle, adipose tissue, and plasma were collected for half of
the mice in each group (max cmp). For the remaining mice, compound-formulated HFD was replaced with control HFD for 24 hours (washout),
followed by similar sample collection. Detected changes in hepatic intermediates of glucose metabolism (Panel A) and long chain fatty acids
(Panel B) for both R118 and metformin-treated mice are shown relative to control HFD in heatmap format. Biochemical data were analyzed using
Welch’s two-sample t-tests.
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pathway were sustained and increased further with
metformin washout. Examination of the detected purine
metabolites across liver, skeletal muscle, and adipose
revealed no obvious candidate tissue targeted by metfor-
min that is primarily responsible for the systemic changes
(data not shown). In a separate study, we have observed
dose-dependent elevations in both plasma xanthine
and uric acid from DIO mice after chronic treatment
with increasing doses of metformin-formulated HFD
(Additional file 3: Figure S3) whereas these metabolites
were slightly decreased with R118 at 300 mg/kg HFD,
suggesting that this pathway is indeed altered with metfor-
min treatment. These metabolites were significantly
increased in plasma samples from mice collected at
two different time points in the active period, reinfor-
cing the observations made in the metabolomics
analysis.Discussion
R118 and metformin indirectly activate AMPK by
inhibiting complex I of the mitochondrial respiratory
chain, although R118 is more potent in vitro against
both these molecular targets compared to metformin.
The compounds display similar activities in cellular assays
of glucose and fat metabolism (data not shown), albeit
with significant differences in potency between metformin
compared to R118. Chronic treatment with each of these
compounds improves systemic glucose homeostasis in
DIO mice. Despite having a similar mechanism of action,
our metabolomics study presented here highlights the
contrast in tissue-selective effects of the two compounds
on metabolic pathways, with a more profound impact of
metformin observed on liver metabolic pathways and
R118 on skeletal muscle.
Plasma BHBA was elevated with both R118 and
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Figure 5 Acute elevation in BHBA levels mediated by both R118 and metformin. Male HFD DIO C57BL/6 mice (21 weeks old, 17 weeks on
HFD) were fed using control HFD, HFD formulated with 200 mg/kg R118, or HFD formulated with 5 g/kg metformin (n = 12/group). After five
weeks of treatment, liver, skeletal muscle, adipose tissue, and plasma were collected for half of the mice in each group (max compound). For the
remaining mice, compound-formulated HFD was replaced with control HFD for 24 hours (washout), followed by similar sample collection. Box
plots are shown of BHBA measurements from plasma, liver, skeletal muscle, and adipose tissue from R118-fed, metformin-fed, and control HFD
fed animals, both in the presence of drug and after drug washout. Data are scaled such that the median value measured across all samples was
set to 1.0. * represents p < 0.05; # represents 0.05 < p < 0.1.
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Despite the effects on LCFA species in liver and skeletal
muscle becoming more marked with washout of metformin
and R118 respectively, BHBA levels in all matrices returned
to control levels when both drugs were removed, suggesting
that BHBA elevation is an acute marker for the inhibitory
activity of each drug against complex I rather than a chronic
adaptation to repeated AMPK stimulation. Complex I
functions to transfer electrons from nicotinamide adenine
dinucleotide hydrate (NADH) to the mitochondrial re-
spiratory chain, and in the process regenerates nicotina-
mide adenine dinucleotide (NAD+). When the drugs are
present, complete TCA cycle oxidation of the acetyl CoAmolecules released by increased breakdown of LCFAs is
likely impaired due to the complex I block. Acetyl CoA
molecules in excess of TCA cycle capacity may be
converted to BHBA in a reaction that produces NAD+,
helping to compensate for reduced complex I function.
Elevated plasma BHBA levels were also observed in db/db
leptin receptor-deficient mice orally dosed with R419, a
mechanistic analog of R118, providing additional support
for BHBA as a marker for complex I inhibition [4].
Repeated stimulation of AMPK, such as occurs with
endurance training, induces metabolic remodeling of
skeletal muscle [19-21]. These adaptations serve to increase



























R118 MET R118 MET
CTRL CTRL CTRL CTRL
xanthosine 0.76 1.67 1.27 4.32
inosine 0.97 1.41 0.93 2.47
urate 0.9 1.51 1.04 1.68










Figure 6 Chronic metformin treatment results in increased plasma levels of purine metabolites. Male HFD DIO C57BL/6 mice (21 weeks
old, 17 weeks on HFD) were fed using control HFD, HFD formulated with 200 mg/kg R118, or HFD formulated with 5 g/kg metformin (n = 12/group).
After five weeks of treatment, liver, skeletal muscle, adipose tissue, and plasma were collected for half of the mice in each group (max cmp). For the
remaining mice, compound-formulated HFD was replaced with control HFD for 24 hours (washout), followed by similar sample collection. Detected
changes in plasma purine metabolites for both R118 and metformin-treated mice are shown relative to control HFD in heatmap format, along with a
schematic illustrating the purine catabolism pathway. Intermediates highlighted using red boxes are significantly elevated in metformin
washout samples.
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maintain metabolic homeostasis during periods of energetic
deficit. R118 increased exercise capacity in HFD-fed mice,
which was accompanied by increased activity of skeletal
muscle citrate synthase, a mitochondrial enzyme [1]. In the
present study, chronic R118 treatment increased skeletal
muscle glucose uptake and metabolism. Additionally, the
increases in the levels of downstream glycolytic intermedi-
ates along with unchanged lactate support an increase in
oxidative metabolism of glucose, which would be consistent
with the increased mitochondrial function suggested by the
elevated citrate synthase activity.
Another adaptation that occurs in response to endurance
exercise training is an increased utilization of lipids for
adenosine triphosphate (ATP) production [22,23]. Factors
contributing to this increased reliance on lipid fuels include
increased oxidative capacity due to greater mitochondrial
density, enhanced nutrient and oxygen delivery to skeletal
muscle resulting from increased capillary density, and also
increased mobilization and transport of fatty acids [24],processes that are coordinately regulated. Lipid fuels can
either come from plasma, which contains adipose-derived
LCFAs liberated via triacylglycerol (TAG) lipolysis, or
from increased lipolysis of intramuscular TAGs [25-27].
R118-treated skeletal muscle displayed concurrent eleva-
tions in several LCFAs as well as glycerol, indicative of
intramuscular TAG lipolysis, both in the presence of drug
and also when drug was removed (Figure 3). Although the
increased exercise performance resulting from R118
treatment of aged, obese mice was mainly attributed to
R118-mediated normalization of microvascular function,
skeletal muscle citrate synthase activity was also increased,
indicating an improvement in mitochondrial function
which could also have a positive effect on exercise capacity.
The impact of metformin on skeletal muscle glucose
metabolism in our study is minimal, especially when
compared to R118. The direct effects of metformin on
skeletal muscle insulin resistance are still debated [8,9]
although metformin treatment has been shown to increase
muscle AMPK activity in human subjects [28]. In this
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10 weeks of treatment. However, this was accompanied by
a small but significant decrease in mean body weight.
Glucose disposal was proposed to occur mainly through
nonoxidative mechanisms; no increase in glucose oxidation
was detected whereas muscle glycogen content was
increased. No significant effects on skeletal muscle
glycogen metabolism were observed for metformin in
this metabolomics study (data not shown) but the pattern
in the levels of detected glycolytic intermediates is
consistent with nonoxidative glucose disposal.
The overall reduction in hepatic LCFAs observed with
chronic metformin treatment correlates well with the
selective effects of metformin in HFD-fed wild type
mice but not mice expressing alanine knock-in mutations
at the AMPK phosphorylation sites in both ACC1 and
ACC2 (AccDKI) [13]. In contrast to the wild type mice
where metformin treatment reduced hepatic lipid content,
metformin had no effects on hepatic lipid levels or hepatic
insulin sensitivity in the AccDKI mice, highlighting the
importance of AMPK-mediated regulation of lipid metab-
olism in the liver in the improved maintenance of glucose
homeostasis observed with chronic metformin treatment.
One clear distinction between the two compounds was
the novel finding that several intermediates of purine
metabolism were elevated in plasma from metformin-
treated but not R118-treated DIO mice. This elevation
was further enhanced with drug washout, which suggests
that this is a chronic effect of metformin dosing. We
analyzed plasma from an independent metformin
dose-titration study performed in DIO mice and found
a dose-dependent elevation in both plasma xanthine
and uric acid levels, whereas treatment using R118 at
300 mg/kg in HFD displayed the opposite effect
(Additional file 3: Figure S3). This elevation was de-
tected in plasma samples harvested at two different
time points in the active cycle, providing evidence
that clearly corroborates the results from the in vivo
metabolomics study. These data suggest that metformin
treatment may perturb carbon flow through purine meta-
bolic pathways, an effect that is specific to metformin since
R118 treatment produced opposite results. One alternative
mechanism proposed for indirect activation of AMPK by
metformin is via a direct effect on adenosine deaminase, an
enzyme that catalyzes conversion of adenosine to inosine
[29]. One might then expect a resulting decrease in
metabolite concentrations downstream of adenosine,
the opposite of what was observed in this metabolomics
study. Of interest, it was recently reported that metformin
treatment of breast cancer cells resulted in a significant
accumulation of 5-formimino-tetrahydrofolate, a carrier of
activated one-carbon units that contributes to de novo
purine synthesis [30], a finding which may be related to
the increase in purine catabolism observed here.Conclusions
In conclusion, our study clearly demonstrates distinct
tissue-selective effects of R118 and metformin on nutrient
metabolism, despite the characterization of both com-
pounds as complex I inhibitors that display similar cellular
and pharmacological activities. R118 elicited more pro-
found changes in glucose and lipid metabolism than
metformin in skeletal muscle, changes that may have
contributed to the enhancements in exercise capacity
reported for R118 in aged, obese mice and if translatable
to humans, may be beneficial in the treatment of muscle
complications resulting from metabolic dysfunction.
Additional files
Additional file 1: Figure S1. Improvement of glucose tolerance by
both R118 and metformin in DIO mice used for the metabolomics
analysis. Male HFD DIO C57BL/6 mice (21 weeks old, 17 weeks on HFD)
were fed using control HFD, HFD formulated with 200 mg/kg R18, or
HFD formulated with 5 g/kg metformin (n = 12/group). A: OGTT and
glucose AUC (area under the curve) following 4-week treatment. GraphPad
Prism version 6.0 was used for 2-way (OGTT) and 1-way (glucose AUC)
ANOVA analysis of data as well as calculation of glucose AUC. Asterisks *, **,
and **** represent p < 0.05, p < 0.01, and p < 0.0001, respectively. B: Body
weight gain during 5-week treatment period.
Additional file 2: Figure S2. Plasma drug levels in samples harvested
in the presence of drug and 24 hours after drug washout. Male HFD DIO
C57BL/6 mice (21 weeks old, 17 weeks on HFD) were fed using control
HFD, HFD formulated with 200 mg/kg R18, or HFD formulated with
5 g/kg metformin (n = 12/group). After five weeks of treatment, plasma
samples were collected as in Figure 1 and analyzed by LC/MS/MS to
quantitatively determine R118 and metformin concentration values.
BLOQ: below limit of quantitation.
Additional file 3: Figure S3. Serum xanthine and uric acid levels in
DIO mice dosed for 6 weeks using either R118 300 mg/kg HFD or
increasing doses of metformin (2.5 g/kg, 5 g/kg, 7.5 g/kg, and 10 g/kg
HFD) (n = 12/group). Blood was collected from three mice/group at 4
different timepoints: 6 AM, 10 AM, 4 PM, and 9 PM. Data are shown for
the 6 AM and 9 PM timepoints, when mice are still in their active cycle.
Serum xanthine and uric acid levels were measured using commercially
available kits (Life Technologies). Data was analyzed in GraphPad Prism
version 6.0 using 1-way ANOVA with Dunnett’s test against the HFD
control. Asterisks *, ** and **** represent p < 0.05, p < 0.01, and p < 0.0001,
respectively.
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